Skip to main content
Equibles
ESLA logo

ESLA · Estrella Immunopharma, Inc. · Metrics

Track ESLA — free

Use ESLA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ESLA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.47 -0.01 (-1.47%) At close · Oct 2
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“As a result, management has determined that there is a substantial doubt about its ability to continue as a going concern. If the Company is unable to obtain adequate financing or generate significant revenue, it may be required to curtail or cease its operations.”
View the 10-Q filed Aug 13, 2026
Market Cap
$20.92M
Shares
43.50M
Volume · Oct 2 14.49K Avg daily vol (3M) 37.45K

ESLA metrics

32 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.47
Market cap
$20.92M

Price action

20 metrics
Price change (1W)
-2.7%
Price change (30D)
-27.6%
Price change (3M)
-52.4%
Price change (6M)
-55.4%
Price change (YTD)
-70.0%
Price change (1Y)
-64.5%
Trailing year
Price change (5Y)
-95.3%
52-week high
$3.05
52-week low
$0.43
Change from 52-week high
-84.7%
Change from 52-week low
+8.5%
Annualized volatility
112.8%
Annualized volatility (3M)
73.4%
Beta
0.7
RSI (14D)
31.1
Price vs SMA 50
-28.5%
Price vs SMA 200
-56.5%
Avg volume (3M)
37,445
Relative volume
0.4
Average dollar volume
$26,430

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
43.50M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
—
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
—

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
—
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
—
Debt / equity
—
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
—
Total assets
—
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
—
Capital expenditures (TTM)
—
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
—
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
23
13F filer change QoQ
-1
Institutional ownership
12.2%

Short interest

3 metrics
Short interest
0.4%
Latest settlement · 4.2 days to cover
Days to cover
4.2d
Short-squeeze score
40 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1844417 CUSIP 297584104 13F (30d) 1 filings 1 filers Visit website Investor relations